Information

Related Research Units

Hla Laboratory Research
Vascular Biology Program Research

Research Overview

Dr. Timothy Hla's laboratory has been investigating the role of lipid mediators, sphingosine 1-phosphate (S1P) and prostanoids in vascular biology and disease. In the 1990s, we cloned the inducible cyclooxygenase (COX-2) and the first S1P receptor. Our work defined how the COX-2 pathway regulated angiogenesis, cancer and inflammatory disease. Recently, we are examining molecular mechanisms by which prostanoids interact with other lipid signaling systems to protect the vascular system and maintain health. Secondly, since our discovery of the S1P receptor we have been working on this novel signaling pathway to understand how it regulates vascular development and homeostasis and is dysregulated in vascular diseases. In addition, our work contributed to the development of S1P receptor inhibitors, which are being tested and used for treatment of a number of autoimmune diseases.

Recently, we discovered that HDL-bound S1P activates vascular S1P receptors to inhibit vascular injury and disease. We also showed that proteins that bind to S1P, such as the HDL-bound apolipoprotein M (ApoM), direct specific biological functions of S1P by activating S1P receptors in unique ways. This mode of signaling, termed as, chaperone-dependent S1P signaling, may be a general mechanism for lipid mediators that are poorly soluble in water. We are also examining novel mechanisms of S1P metabolism, export into the extracellular environment, capture and signaling by novel chaperones, receptor-dependent signaling mechanisms and cross-talk with other cytokine, growth factor signaling pathways. Such mechanistic information is useful not only to achieve a deeper understanding of vascular health and disease but also to develop new therapeutic entities based on the S1P signaling system, In fact, our laboratory is developing novel small molecular as well as protein biotherapeutics with the potential to modulate diseases such as heart disease, stroke, autoimmune diseases, eye disease and cancer.

 

Research Background

Timothy Hla received his Ph.D. in biochemistry from The George Washington University. Following a post-doctoral training period in which he worked in the lab of Thomas Maciag, he started his laboratory at the Holland Laboratory at the American Red Cross, Rockville, MD. He was recruited to the University of Connecticut School of Medicine in Farmington, CT where he founded the research Center for Vascular Biology and was eventually promoted to Professor. In 2009, he was recruited as a Professor and Director of the Center for Vascular Biology at Weill Cornell Medicine, Cornell University. He moved his research program to Boston Children's Hospital in 2016 where he is appointed as an investigator at the Vascular Biology Program and Patricia K. Donohoe Professor of Surgery at the Harvard Medical School. Dr. Hla is an honorary member of the Japanese Biochemical Society, received an honorary M.D. degree from the Geothe University, Frankfurt, Germany and a MERIT award from the NHLBI, NIH in 2006.

Publications

  1. Withdrawal: Lysophosphatidic acid stimulates the G-protein-coupled receptor EDG-1 as a low affinity agonist. J Biol Chem. 2024 08; 300(8):107597. View Abstract
  2. Regulation of cellular and systemic sphingolipid homeostasis. Nat Rev Mol Cell Biol. 2024 Oct; 25(10):802-821. View Abstract
  3. Endothelial cell sphingosine 1-phosphate receptor 1 restrains VE-cadherin cleavage and attenuates experimental inflammatory arthritis. JCI Insight. 2024 Jun 10; 9(11). View Abstract
  4. The sphinx helps to answer the riddle of cardiac regeneration. Trends Endocrinol Metab. 2024 Aug; 35(8):677-679. View Abstract
  5. The ß-catenin C terminus links Wnt and sphingosine-1-phosphate signaling pathways to promote vascular remodeling and atherosclerosis. Sci Adv. 2024 Mar 15; 10(11):eadg9278. View Abstract
  6. Designer high-density lipoprotein particles enhance endothelial barrier function and suppress inflammation. Sci Signal. 2024 02 20; 17(824):eadg9256. View Abstract
  7. Augmentation of Endothelial S1PR1 Attenuates Postviral Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2024 Feb; 70(2):119-128. View Abstract
  8. Report from the 2023 workshop on endothelial permeability, edema and inflammation. Nat Cardiovasc Res. 2023 12; 2(12):1120-1124. View Abstract
  9. Therapeutic activation of endothelial sphingosine-1-phosphate receptor 1 by chaperone-bound S1P suppresses proliferative retinal neovascularization. EMBO Mol Med. 2023 05 08; 15(5):e16645. View Abstract
  10. Signal Transduction and Gene Regulation in the Endothelium. Cold Spring Harb Perspect Med. 2023 01 03; 13(1). View Abstract
  11. Murine endothelial serine palmitoyltransferase 1 (SPTLC1) is required for vascular development and systemic sphingolipid homeostasis. Elife. 2022 Oct 05; 11. View Abstract
  12. Retraction: Obesity Is Associated With Inflammation and Elevated Aromatase Expression in the Mouse Mammary Gland. Cancer Prev Res (Phila). 2022 06 02; 15(6):413. View Abstract
  13. Sphingosine 1-phosphate receptor-targeted therapeutics in rheumatic diseases. Nat Rev Rheumatol. 2022 06; 18(6):335-351. View Abstract
  14. Corrigendum to "Sphingosine 1-phosphate receptor 1 regulates cell-surface localization of membrane proteins in endothelial cells" [Biochim Biophys Acta Gen Subj. volume 1863 (6) (2019) 1079-1087]. Biochim Biophys Acta Gen Subj. 2022 Aug; 1866(8):130138. View Abstract
  15. DOCK4 Regulation of Rho GTPases Mediates Pulmonary Vascular Barrier Function. Arterioscler Thromb Vasc Biol. 2022 07; 42(7):886-902. View Abstract
  16. Endothelial-Specific Loss of Sphingosine-1-Phosphate Receptor 1 Increases Vascular Permeability and Exacerbates Bleomycin-induced Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2022 01; 66(1):38-52. View Abstract
  17. Plasma components to protect the endothelial barrier after shock: A role for sphingosine 1-phosphate. Surgery. 2022 03; 171(3):825-832. View Abstract
  18. Lysophospholipid Mediators in Health and Disease. Annu Rev Pathol. 2022 01 24; 17:459-483. View Abstract
  19. Endothelial Spns2 and ApoM Regulation of Vascular Tone and Hypertension Via Sphingosine-1-Phosphate. J Am Heart Assoc. 2021 07 20; 10(14):e021261. View Abstract
  20. CLIC1 and CLIC4 mediate endothelial S1P receptor signaling to facilitate Rac1 and RhoA activity and function. Sci Signal. 2021 04 20; 14(679). View Abstract
  21. Support Myanmar's embattled scientists and students. Nature. 2021 04; 592(7855):507. View Abstract
  22. Lysolipids in Vascular Development, Biology, and Disease. Arterioscler Thromb Vasc Biol. 2021 02; 41(2):564-584. View Abstract
  23. Endothelial S1P1 Signaling Counteracts Infarct Expansion in Ischemic Stroke. Circ Res. 2021 02 05; 128(3):363-382. View Abstract
  24. S1PR1 regulates the quiescence of lymphatic vessels by inhibiting laminar shear stress-dependent VEGF-C signaling. JCI Insight. 2020 07 23; 5(14). View Abstract
  25. Aging Suppresses Sphingosine-1-Phosphate Chaperone ApoM in Circulation Resulting in Maladaptive Organ Repair. Dev Cell. 2020 06 22; 53(6):677-690.e4. View Abstract
  26. Sphingosine 1-phosphate-regulated transcriptomes in heterogenous arterial and lymphatic endothelium of the aorta. Elife. 2020 02 24; 9. View Abstract
  27. Sphingosine 1-Phosphate Receptor Signaling Establishes AP-1 Gradients to Allow for Retinal Endothelial Cell Specialization. Dev Cell. 2020 03 23; 52(6):779-793.e7. View Abstract
  28. Sphingosine kinases protect murine embryonic stem cells from sphingosine-induced cell cycle arrest. Stem Cells. 2020 05; 38(5):613-623. View Abstract
  29. Endothelial sphingosine 1-phosphate receptors promote vascular normalization and antitumor therapy. Proc Natl Acad Sci U S A. 2020 02 11; 117(6):3157-3166. View Abstract
  30. Withdrawal: EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells: Evidence of a BRCA1 and p300 exchange. J Biol Chem. 2020 01 03; 295(1):295. View Abstract
  31. Withdrawal: EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells: Evidence of a BRCA1 and p300 exchange. J Biol Chem. 2020 Jan 03; 295(1):295. View Abstract
  32. Post-transcriptional regulation of Nrf2-mRNA by the mRNA-binding proteins HuR and AUF1. FASEB J. 2019 12; 33(12):14636-14652. View Abstract
  33. Sphingosine 1-phosphate: Lipid signaling in pathology and therapy. Science. 2019 10 18; 366(6463). View Abstract
  34. TLR4 (Toll-Like Receptor 4)-Dependent Signaling Drives Extracellular Catabolism of LDL (Low-Density Lipoprotein) Aggregates. Arterioscler Thromb Vasc Biol. 2020 01; 40(1):86-102. View Abstract
  35. Identification of ApoA4 as a sphingosine 1-phosphate chaperone in ApoM- and albumin-deficient mice. J Lipid Res. 2019 11; 60(11):1912-1921. View Abstract
  36. Sphingosine 1-phosphate and inflammation. Int Immunol. 2019 08 23; 31(9):617-625. View Abstract
  37. Myeloid sphingosine-1-phosphate receptor 1 is important for CNS autoimmunity and neuroinflammation. J Autoimmun. 2019 12; 105:102290. View Abstract
  38. Upregulation of sphingosine-1-phosphate receptor 3 on fibroblast-like synoviocytes is associated with the development of collagen-induced arthritis via increased interleukin-6 production. PLoS One. 2019; 14(6):e0218090. View Abstract
  39. Lysolipid receptor cross-talk regulates lymphatic endothelial junctions in lymph nodes. J Exp Med. 2019 07 01; 216(7):1582-1598. View Abstract
  40. Sphingosine 1-phosphate receptor 1 regulates cell-surface localization of membrane proteins in endothelial cells. Biochim Biophys Acta Gen Subj. 2019 06; 1863(6):1079-1087. View Abstract
  41. Abrogation of Endogenous Glycolipid Antigen Presentation on Myelin-Laden Macrophages by D-Sphingosine Ameliorates the Pathogenesis of Experimental Autoimmune Encephalomyelitis. Front Immunol. 2019; 10:404. View Abstract
  42. CD4 T cell sphingosine 1-phosphate receptor (S1PR)1 and S1PR4 and endothelial S1PR2 regulate afferent lymphatic migration. Sci Immunol. 2019 03 15; 4(33). View Abstract
  43. Lipid Mediators, M2 Macrophages, and Pathological Neovascularization. Trends Mol Med. 2018 12; 24(12):977-978. View Abstract
  44. Sphingosine 1-Phosphate Receptor 1 Signaling Maintains Endothelial Cell Barrier Function and Protects Against Immune Complex-Induced Vascular Injury. Arthritis Rheumatol. 2018 11; 70(11):1879-1889. View Abstract
  45. Colonoscopic-Guided Pinch Biopsies in Mice as a Useful Model for Evaluating the Roles of Host and Luminal Factors in Colonic Inflammation. Am J Pathol. 2018 12; 188(12):2811-2825. View Abstract
  46. Bioactive lysolipids in cancer and angiogenesis. Pharmacol Ther. 2019 01; 193:91-98. View Abstract
  47. Cell-intrinsic sphingosine kinase 2 promotes macrophage polarization and renal inflammation in response to unilateral ureteral obstruction. PLoS One. 2018; 13(3):e0194053. View Abstract
  48. A dark side to omega-3 fatty acids. Nature. 2017 12 14; 552(7684):180-181. View Abstract
  49. A dark side to omega-3 fatty acids. Nature. 2017 Dec; 552(7684):180-181. View Abstract
  50. Bioluminescence imaging of G protein-coupled receptor activation in living mice. Nat Commun. 2017 10 27; 8(1):1163. View Abstract
  51. The ceramide synthase 2b gene mediates genomic sensing and regulation of sphingosine levels during zebrafish embryogenesis. Elife. 2017 09 28; 6. View Abstract
  52. Ceramide activation of RhoA/Rho kinase impairs actin polymerization during aggregated LDL catabolism. J Lipid Res. 2017 10; 58(10):1977-1987. View Abstract
  53. An engineered S1P chaperone attenuates hypertension and ischemic injury. Sci Signal. 2017 Aug 15; 10(492). View Abstract
  54. Correction: TRAF2 regulates TNF and NF-?B signalling to suppress apoptosis and skin inflammation independently of Sphingosine kinase 1. Elife. 2017 06 27; 6. View Abstract
  55. S1PR1 (Sphingosine-1-Phosphate Receptor 1) Signaling Regulates Blood Flow and Pressure. Hypertension. 2017 08; 70(2):426-434. View Abstract
  56. Quality Versus Quantity: Making HDL Great Again. Arterioscler Thromb Vasc Biol. 2017 06; 37(6):1018-1019. View Abstract
  57. Lymphatic endothelial S1P promotes mitochondrial function and survival in naive T cells. Nature. 2017 06 01; 546(7656):158-161. View Abstract
  58. Size-selective opening of the blood-brain barrier by targeting endothelial sphingosine 1-phosphate receptor 1. Proc Natl Acad Sci U S A. 2017 04 25; 114(17):4531-4536. View Abstract
  59. HDL activation of endothelial sphingosine-1-phosphate receptor-1 (S1P1) promotes regeneration and suppresses fibrosis in the liver. JCI Insight. 2016 Dec 22; 1(21):e87058. View Abstract
  60. Vascular and Immunobiology of the Circulatory Sphingosine 1-Phosphate Gradient. Annu Rev Physiol. 2017 02 10; 79:67-91. View Abstract
  61. Platelet and Erythrocyte Sources of S1P Are Redundant for Vascular Development and Homeostasis, but Both Rendered Essential After Plasma S1P Depletion in Anaphylactic Shock. Circ Res. 2016 Sep 30; 119(8):e110-26. View Abstract
  62. Sphingosine kinases are not required for inflammatory responses in macrophages. J Biol Chem. 2016 May 20; 291(21):11465. View Abstract
  63. Impaired endothelial barrier function in apolipoprotein M-deficient mice is dependent on sphingosine-1-phosphate receptor 1. FASEB J. 2016 06; 30(6):2351-9. View Abstract
  64. TRAF2 regulates TNF and NF-?B signalling to suppress apoptosis and skin inflammation independently of Sphingosine kinase 1. Elife. 2015 Dec 23; 4. View Abstract
  65. Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis. Nat Med. 2015 Nov; 21(11):1290-7. View Abstract
  66. Nogo-B regulates endothelial sphingolipid homeostasis to control vascular function and blood pressure. Nat Med. 2015 Sep; 21(9):1028-1037. View Abstract
  67. HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation. Sci Signal. 2015 Aug 11; 8(389):ra79. View Abstract
  68. Maternal or zygotic sphingosine kinase is required to regulate zebrafish cardiogenesis. Dev Dyn. 2015 Aug; 244(8):948-54. View Abstract
  69. Antitumor Activity of a Novel Sphingosine-1-Phosphate 2 Antagonist, AB1, in Neuroblastoma. J Pharmacol Exp Ther. 2015 Sep; 354(3):261-8. View Abstract
  70. HDL-bound sphingosine-1-phosphate restrains lymphopoiesis and neuroinflammation. Nature. 2015 Jul 16; 523(7560):342-6. View Abstract
  71. Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J Clin Invest. 2015 Apr; 125(4):1379-87. View Abstract
  72. ELAVL1 modulates transcriptome-wide miRNA binding in murine macrophages. Cell Rep. 2014 Dec 24; 9(6):2330-43. View Abstract
  73. ELAVL1 regulates alternative splicing of eIF4E transporter to promote postnatal angiogenesis. Proc Natl Acad Sci U S A. 2014 Dec 23; 111(51):18309-14. View Abstract
  74. C16:0-ceramide signals insulin resistance. Cell Metab. 2014 Nov 04; 20(5):703-705. View Abstract
  75. Individual variation of human S1P1 coding sequence leads to heterogeneity in receptor function and drug interactions. J Lipid Res. 2014 Dec; 55(12):2665-75. View Abstract
  76. Erythrocyte-derived sphingosine 1-phosphate is essential for vascular development. J Clin Invest. 2014 Nov; 124(11):4823-8. View Abstract
  77. Knock out of S1P3 receptor signaling attenuates inflammation and fibrosis in bleomycin-induced lung injury mice model. PLoS One. 2014; 9(9):e106792. View Abstract
  78. The BCL6 RD2 domain governs commitment of activated B cells to form germinal centers. Cell Rep. 2014 Sep 11; 8(5):1497-508. View Abstract
  79. Intestinal epithelial HuR modulates distinct pathways of proliferation and apoptosis and attenuates small intestinal and colonic tumor development. Cancer Res. 2014 Sep 15; 74(18):5322-35. View Abstract
  80. Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications. Am Heart J. 2014 Nov; 168(5):632-44. View Abstract
  81. Sphingosine-1-phosphate receptor 1 signalling in T cells: trafficking and beyond. Immunology. 2014 Jul; 142(3):347-53. View Abstract
  82. Induction of chemokine (C-C motif) ligand 2 by sphingosine-1-phosphate signaling in neuroblastoma. J Pediatr Surg. 2014 Aug; 49(8):1286-91. View Abstract
  83. Post-transcriptional gene regulation by HuR and microRNAs in angiogenesis. Curr Opin Hematol. 2014 May; 21(3):235-40. View Abstract
  84. Treatment with the immunomodulator FTY720 (fingolimod) significantly reduces renal inflammation in murine unilateral ureteral obstruction. J Urol. 2014 May; 191(5 Suppl):1508-16. View Abstract
  85. An update on the biology of sphingosine 1-phosphate receptors. J Lipid Res. 2014 Aug; 55(8):1596-608. View Abstract
  86. Elavl1a regulates zebrafish erythropoiesis via posttranscriptional control of gata1. Blood. 2014 Feb 27; 123(9):1384-92. View Abstract
  87. Sphingosine 1-phosphate signalling. Development. 2014 Jan; 141(1):5-9. View Abstract
  88. S1P control of endothelial integrity. Curr Top Microbiol Immunol. 2014; 378:85-105. View Abstract
  89. Sphingosine kinases are not required for inflammatory responses in macrophages. J Biol Chem. 2013 Nov 08; 288(45):32563-32573. View Abstract
  90. Defective sphingosine 1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammation. Nat Immunol. 2013 Nov; 14(11):1166-72. View Abstract
  91. FTY720 inhibits tumor growth and enhances the tumor-suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway. Pediatr Blood Cancer. 2013 Sep; 60(9):1418-23. View Abstract
  92. Genetic deletion of microsomal prostaglandin E synthase-1 suppresses mouse mammary tumor growth and angiogenesis. Prostaglandins Other Lipid Mediat. 2013 Oct; 106:99-105. View Abstract
  93. S1P1 localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity. J Lipid Res. 2013 Mar; 54(3):843-851. View Abstract
  94. Sphingosine 1-phosphate receptor signaling regulates proper embryonic vascular patterning. J Biol Chem. 2013 Jan 25; 288(4):2143-56. View Abstract
  95. Antagonistic function of the RNA-binding protein HuR and miR-200b in post-transcriptional regulation of vascular endothelial growth factor-A expression and angiogenesis. J Biol Chem. 2013 Feb 15; 288(7):4908-21. View Abstract
  96. S1P and the birth of platelets. J Exp Med. 2012 Nov 19; 209(12):2137-40. View Abstract
  97. Regulation of a vascular plexus by gata4 is mediated in zebrafish through the chemokine sdf1a. PLoS One. 2012; 7(10):e46844. View Abstract
  98. Fine-tuning S1P therapeutics. Chem Biol. 2012 Sep 21; 19(9):1080-2. View Abstract
  99. Sphingolipid signaling in metabolic disorders. Cell Metab. 2012 Oct 03; 16(4):420-34. View Abstract
  100. Flow-regulated endothelial S1P receptor-1 signaling sustains vascular development. Dev Cell. 2012 Sep 11; 23(3):600-10. View Abstract
  101. Sphingosine 1-phosphate (S1P)/S1P receptor 1 signaling regulates receptor activator of NF-?B ligand (RANKL) expression in rheumatoid arthritis. Biochem Biophys Res Commun. 2012 Mar 09; 419(2):154-9. View Abstract
  102. SnapShot: Bioactive lysophospholipids. Cell. 2012 Jan 20; 148(1-2):378-378.e2. View Abstract
  103. Assessment of sphingosine-1-phosphate activity in biological samples by receptor internalization and adherens junction formation. Methods Mol Biol. 2012; 874:69-76. View Abstract
  104. Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors. Chem Rev. 2011 Oct 12; 111(10):6299-320. View Abstract
  105. Sphingosine 1-phosphate in coagulation and inflammation. Semin Immunopathol. 2012 Jan; 34(1):73-91. View Abstract
  106. Gene regulation by RNA binding proteins and microRNAs in angiogenesis. Trends Mol Med. 2011 Nov; 17(11):650-8. View Abstract
  107. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci U S A. 2011 Jun 07; 108(23):9613-8. View Abstract
  108. Sphingolipid modulation of angiogenic factor expression in neuroblastoma. Cancer Prev Res (Phila). 2011 Aug; 4(8):1325-32. View Abstract
  109. Engagement of S1P1-degradative mechanisms leads to vascular leak in mice. J Clin Invest. 2011 Jun; 121(6):2290-300. View Abstract
  110. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila). 2011 Mar; 4(3):329-46. View Abstract
  111. Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation. Neurology. 2011 Feb 22; 76(8 Suppl 3):S3-8. View Abstract
  112. International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol Rev. 2010 Dec; 62(4):579-87. View Abstract
  113. Sphingosine-1-phosphate receptor-2 function in myeloid cells regulates vascular inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol. 2011 Jan; 31(1):81-5. View Abstract
  114. Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics. J Exp Med. 2010 Jul 05; 207(7):1475-83. View Abstract
  115. Sphingosine interaction with acidic leucine-rich nuclear phosphoprotein-32A (ANP32A) regulates PP2A activity and cyclooxygenase (COX)-2 expression in human endothelial cells. J Biol Chem. 2010 Aug 27; 285(35):26825-26831. View Abstract
  116. Inhibitory role of sphingosine 1-phosphate receptor 2 in macrophage recruitment during inflammation. J Immunol. 2010 Feb 01; 184(3):1475-83. View Abstract
  117. Ramping up RANTES in the acute response to arterial injury. J Clin Invest. 2010 Jan; 120(1):90-2. View Abstract
  118. Essential role of the RNA-binding protein HuR in progenitor cell survival in mice. J Clin Invest. 2009 Dec; 119(12):3530-43. View Abstract
  119. Plugging vascular leak by sphingosine kinase from bone marrow progenitor cells. Circ Res. 2009 Sep 25; 105(7):614-6. View Abstract
  120. Galpha(q)-mediated plasma membrane translocation of sphingosine kinase-1 and cross-activation of S1P receptors. Biochim Biophys Acta. 2009 May; 1791(5):357-70. View Abstract
  121. Regulation of vascular physiology and pathology by the S1P2 receptor subtype. Cardiovasc Res. 2009 May 01; 82(2):221-8. View Abstract
  122. Cell biology. The ABCs of lipophile transport. Science. 2009 Feb 13; 323(5916):883-4. View Abstract
  123. S1P/S1P2 signaling induces cyclooxygenase-2 expression in Wilms tumor. J Urol. 2009 Mar; 181(3):1347-52. View Abstract
  124. S1P/S1P1 signaling stimulates cell migration and invasion in Wilms tumor. Cancer Lett. 2009 Apr 18; 276(2):171-9. View Abstract
  125. PPARdelta is pro-tumorigenic in a mouse model of COX-2-induced mammary cancer. Prostaglandins Other Lipid Mediat. 2009 Apr; 88(3-4):97-100. View Abstract
  126. Lysophospholipid receptors in vertebrate development, physiology, and pathology. J Lipid Res. 2009 Apr; 50 Suppl:S293-8. View Abstract
  127. Induction of antiproliferative connective tissue growth factor expression in Wilms' tumor cells by sphingosine-1-phosphate receptor 2. Mol Cancer Res. 2008 Oct; 6(10):1649-56. View Abstract
  128. Up-regulating sphingosine 1-phosphate receptor-2 signaling impairs chemotactic, wound-healing, and morphogenetic responses in senescent endothelial cells. J Biol Chem. 2008 Oct 31; 283(44):30363-75. View Abstract
  129. The vascular S1P gradient-cellular sources and biological significance. Biochim Biophys Acta. 2008 Sep; 1781(9):477-82. View Abstract
  130. Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res. 2008 Mar 28; 102(6):669-76. View Abstract
  131. Role of sphingosine 1-phosphate in the pathogenesis of Sjögren's syndrome. J Immunol. 2008 Feb 01; 180(3):1921-8. View Abstract
  132. Phospholipase C beta3 deficiency leads to macrophage hypersensitivity to apoptotic induction and reduction of atherosclerosis in mice. J Clin Invest. 2008 Jan; 118(1):195-204. View Abstract
  133. EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange. J Biol Chem. 2008 Feb 08; 283(6):3433-3444. View Abstract
  134. Essential role of sphingosine 1-phosphate receptor 2 in pathological angiogenesis of the mouse retina. J Clin Invest. 2007 Sep; 117(9):2506-16. View Abstract
  135. COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activation. J Exp Med. 2007 Sep 03; 204(9):2053-61. View Abstract
  136. A novel method to quantify sphingosine 1-phosphate by immobilized metal affinity chromatography (IMAC). Prostaglandins Other Lipid Mediat. 2007 Nov; 84(3-4):154-62. View Abstract
  137. Sphingosine kinase 1 is a critical component of the copper-dependent FGF1 export pathway. Exp Cell Res. 2007 Sep 10; 313(15):3308-18. View Abstract
  138. Induction of vascular permeability by the sphingosine-1-phosphate receptor-2 (S1P2R) and its downstream effectors ROCK and PTEN. Arterioscler Thromb Vasc Biol. 2007 Jun; 27(6):1312-8. View Abstract
  139. Deafness and stria vascularis defects in S1P2 receptor-null mice. J Biol Chem. 2007 Apr 06; 282(14):10690-6. View Abstract
  140. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J Biol Chem. 2007 Mar 23; 282(12):9082-9. View Abstract
  141. Mapping pathways downstream of sphingosine 1-phosphate subtype 1 by differential chemical perturbation and proteomics. J Biol Chem. 2007 Mar 09; 282(10):7254-64. View Abstract
  142. A festschrift for J. Martyn Bailey, a biochemist extraordinaire. Prostaglandins Other Lipid Mediat. 2007 Feb; 83(1-2):154-7. View Abstract
  143. Intracellular role for sphingosine kinase 1 in intestinal adenoma cell proliferation. Mol Cell Biol. 2006 Oct; 26(19):7211-23. View Abstract
  144. Dual roles of tight junction-associated protein, zonula occludens-1, in sphingosine 1-phosphate-mediated endothelial chemotaxis and barrier integrity. J Biol Chem. 2006 Sep 29; 281(39):29190-200. View Abstract
  145. Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient. Biochem J. 2006 Aug 01; 397(3):461-71. View Abstract
  146. Normal acute and chronic inflammatory responses in sphingosine kinase 1 knockout mice. FEBS Lett. 2006 Aug 21; 580(19):4607-12. View Abstract
  147. Protein kinase Calpha and sphingosine 1-phosphate-dependent signaling in endothelial cell. Prostaglandins Other Lipid Mediat. 2006 Jul; 80(1-2):15-27. View Abstract
  148. HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism. Cancer Res. 2006 May 15; 66(10):5504-11. View Abstract
  149. Sphingosine 1-phosphate/sphingosine 1-phosphate receptor 1 signaling in rheumatoid synovium: regulation of synovial proliferation and inflammatory gene expression. Arthritis Rheum. 2006 Mar; 54(3):742-53. View Abstract
  150. Sphingosine-1-phosphate signaling regulates lamellipodia localization of cortactin complexes in endothelial cells. Histochem Cell Biol. 2006 Sep; 126(3):297-304. View Abstract
  151. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res. 2006 Jan 01; 66(1):221-31. View Abstract
  152. HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res. 2005 Nov 01; 65(21):10113-9. View Abstract
  153. Immunology. Dietary factors and immunological consequences. Science. 2005 Sep 09; 309(5741):1682-3. View Abstract
  154. Genomic insights into mediator lipidomics. Prostaglandins Other Lipid Mediat. 2005 Sep; 77(1-4):197-209. View Abstract
  155. The dawn of lipidomics. Prostaglandins Other Lipid Mediat. 2005 Sep; 77(1-4):1-3. View Abstract
  156. S1P1-selective in vivo-active agonists from high-throughput screening: off-the-shelf chemical probes of receptor interactions, signaling, and fate. Chem Biol. 2005 Jun; 12(6):703-15. View Abstract
  157. The prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia. Cancer Res. 2005 Jun 01; 65(11):4496-9. View Abstract
  158. COX-2 inhibitors and genetic background reduce mammary tumorigenesis in cyclooxygenase-2 transgenic mice. Prostaglandins Other Lipid Mediat. 2005 May; 76(1-4):86-94. View Abstract
  159. The G protein-coupled receptor S1P2 regulates Rho/Rho kinase pathway to inhibit tumor cell migration. Cancer Res. 2005 May 01; 65(9):3788-95. View Abstract
  160. Regulation of vascular endothelial cell growth factor expression in mouse mammary tumor cells by the EP2 subtype of the prostaglandin E2 receptor. Prostaglandins Other Lipid Mediat. 2005 May; 76(1-4):48-58. View Abstract
  161. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res. 2005 Mar 15; 65(6):2157-61. View Abstract
  162. PTEN as an effector in the signaling of antimigratory G protein-coupled receptor. Proc Natl Acad Sci U S A. 2005 Mar 22; 102(12):4312-7. View Abstract
  163. Inhibition of gene expression in vivo using multiplex siRNA. Methods Mol Biol. 2005; 309:197-203. View Abstract
  164. Signaling through 3',5'-cyclic adenosine monophosphate and phosphoinositide-3 kinase induces sodium/iodide symporter expression in breast cancer. J Clin Endocrinol Metab. 2004 Oct; 89(10):5196-203. View Abstract
  165. Physiological and pathological actions of sphingosine 1-phosphate. Semin Cell Dev Biol. 2004 Oct; 15(5):513-20. View Abstract
  166. Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference. J Clin Invest. 2004 Oct; 114(8):1082-9. View Abstract
  167. Sphingosine 1-phosphate receptor regulation of N-cadherin mediates vascular stabilization. Genes Dev. 2004 Oct 01; 18(19):2392-403. View Abstract
  168. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004 Sep; 56(3):387-437. View Abstract
  169. Structural and functional characteristics of S1P receptors. J Cell Biochem. 2004 Aug 01; 92(5):913-22. View Abstract
  170. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant. 2004 Jul; 4(7):1019-25. View Abstract
  171. Regulation of limb development by the sphingosine 1-phosphate receptor S1p1/EDG-1 occurs via the hypoxia/VEGF axis. Dev Biol. 2004 Apr 15; 268(2):441-7. View Abstract
  172. Induction of cyclooxygenase-2 in macrophages by catalase: role of NF-kappaB and PI3K signaling pathways. Biochem Biophys Res Commun. 2004 Apr 02; 316(2):398-406. View Abstract
  173. Point-counterpoint of sphingosine 1-phosphate metabolism. Circ Res. 2004 Apr 02; 94(6):724-34. View Abstract
  174. Constitutive expression of the S1P1 receptor in adult tissues. Prostaglandins Other Lipid Mediat. 2004 Jan; 73(1-2):141-50. View Abstract
  175. Prostaglandins & other lipid mediators: a new phase, a new team. Prostaglandins Other Lipid Mediat. 2004 Jan; 73(1-2):1-2. View Abstract
  176. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A. 2004 Jan 13; 101(2):591-6. View Abstract
  177. Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma. Cancer Res. 2003 Nov 15; 63(22):7591-4. View Abstract
  178. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem. 2003 Nov 21; 278(47):47281-90. View Abstract
  179. Signaling and biological actions of sphingosine 1-phosphate. Pharmacol Res. 2003 May; 47(5):401-7. View Abstract
  180. The RNA-binding protein HuR regulates the expression of cyclooxygenase-2. J Biol Chem. 2003 Jul 04; 278(27):25227-33. View Abstract
  181. Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted from colon cancer cells. Proc Natl Acad Sci U S A. 2003 Mar 04; 100(5):2736-41. View Abstract
  182. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol. 2003 Apr 01; 23(4):594-600. View Abstract
  183. Platelet-derived growth factor (PDGF)-induced chemotaxis does not require the G protein-coupled receptor S1P1 in murine embryonic fibroblasts and vascular smooth muscle cells. FEBS Lett. 2003 Jan 02; 533(1-3):25-8. View Abstract
  184. Sphingosine-1-phosphate signaling in endothelial activation. J Atheroscler Thromb. 2003; 10(3):125-31. View Abstract
  185. Leptomycin B, an inhibitor of the nuclear export receptor CRM1, inhibits COX-2 expression. J Biol Chem. 2003 Jan 31; 278(5):2773-6. View Abstract
  186. Intimal smooth muscle cells as a target for peroxisome proliferator-activated receptor-gamma ligand therapy. Circ Res. 2002 Aug 09; 91(3):210-7. View Abstract
  187. International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. Pharmacol Rev. 2002 Jun; 54(2):265-9. View Abstract
  188. Signaling of sphingosine-1-phosphate via the S1P/EDG-family of G-protein-coupled receptors. Biochim Biophys Acta. 2002 May 23; 1582(1-3):72-80. View Abstract
  189. Prostaglandins and the regulation of tumor growth. J Environ Pathol Toxicol Oncol. 2002; 21(2):93-101. View Abstract
  190. Extracellular export of sphingosine kinase-1 enzyme. Sphingosine 1-phosphate generation and the induction of angiogenic vascular maturation. J Biol Chem. 2002 Feb 22; 277(8):6667-75. View Abstract
  191. Lysophospholipids--receptor revelations. Science. 2001 Nov 30; 294(5548):1875-8. View Abstract
  192. Role of the sphingosine 1-phosphate receptor EDG-1 in vascular smooth muscle cell proliferation and migration. Circ Res. 2001 Sep 14; 89(6):496-502. View Abstract
  193. Akt-mediated phosphorylation of the G protein-coupled receptor EDG-1 is required for endothelial cell chemotaxis. Mol Cell. 2001 Sep; 8(3):693-704. View Abstract
  194. First international conference on lysophospholipids and related bioactive lipids in biology and disease sponsored by the Federation of American Societies of Experimental Biology. ScientificWorldJournal. 2001 Jul 17; 1:269-70. View Abstract
  195. Expression of peroxisome proliferator-activated receptor (PPAR)-gamma in human lung cancer. Anticancer Res. 2001 Jul-Aug; 21(4A):2471-6. View Abstract
  196. Feedback control of the arachidonate cascade in rheumatoid synoviocytes by 15-deoxy-Delta(12,14)-prostaglandin J2. Biochem Biophys Res Commun. 2001 May 18; 283(4):750-5. View Abstract
  197. Sphingosine 1-phosphate receptors. Prostaglandins Other Lipid Mediat. 2001 Apr; 64(1-4):135-42. View Abstract
  198. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem. 2001 May 25; 276(21):18563-9. View Abstract
  199. Sphingosine 1-phosphate activates Akt, nitric oxide production, and chemotaxis through a Gi protein/phosphoinositide 3-kinase pathway in endothelial cells. J Biol Chem. 2001 Jun 01; 276(22):19672-7. View Abstract
  200. Prostaglandin E2 and vasoactive intestinal peptide increase vascular endothelial cell growth factor mRNAs in lung cancer cells. Lung Cancer. 2001 Feb-Mar; 31(2-3):203-12. View Abstract
  201. Sphingosine 1-phosphate-induced endothelial cell migration requires the expression of EDG-1 and EDG-3 receptors and Rho-dependent activation of alpha vbeta3- and beta1-containing integrins. J Biol Chem. 2001 Apr 13; 276(15):11830-7. View Abstract
  202. Serum withdrawal-induced post-transcriptional stabilization of cyclooxygenase-2 mRNA in MDA-MB-231 mammary carcinoma cells requires the activity of the p38 stress-activated protein kinase. J Biol Chem. 2000 Dec 15; 275(50):39507-15. View Abstract
  203. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest. 2000 Oct; 106(8):951-61. View Abstract
  204. Bisphenol A diglycidyl ether (BADGE) is a PPARgamma agonist in an ECV304 cell line. Br J Pharmacol. 2000 Oct; 131(4):651-4. View Abstract
  205. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer. 2000 Aug 01; 89(3):589-96. View Abstract
  206. 15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest. 2000 Jul; 106(2):189-97. View Abstract
  207. Characterization of a novel sphingosine 1-phosphate receptor, Edg-8. J Biol Chem. 2000 May 12; 275(19):14281-6. View Abstract
  208. Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun. 2000 Apr 13; 270(2):400-5. View Abstract
  209. Switching intracellular signaling pathways to study sphingosine 1-phosphate receptors. Ann N Y Acad Sci. 2000 Apr; 905:260-2. View Abstract
  210. Sphingosine-1-phosphate signaling via the EDG-1 family of G-protein-coupled receptors. Ann N Y Acad Sci. 2000 Apr; 905:16-24. View Abstract
  211. Selective inhibition of cyclooxygenase-2 with antisense oligodeoxynucleotide restricts induction of rat adjuvant-induced arthritis. Biochem Biophys Res Commun. 2000 Mar 16; 269(2):415-21. View Abstract
  212. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol. 2000 Feb 01; 164(3):1364-71. View Abstract
  213. Auranofin inhibits interleukin-1beta-induced transcript of cyclooxygenase-2 on cultured human synoviocytes. Eur J Pharmacol. 1999 Nov 26; 385(1):71-9. View Abstract
  214. Overexpression of cyclooxygenase-2 induces cell cycle arrest. Evidence for a prostaglandin-independent mechanism. J Biol Chem. 1999 Nov 26; 274(48):34141-7. View Abstract
  215. Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell. 1999 Oct 29; 99(3):301-12. View Abstract
  216. Differential coupling of the sphingosine 1-phosphate receptors Edg-1, Edg-3, and H218/Edg-5 to the G(i), G(q), and G(12) families of heterotrimeric G proteins. J Biol Chem. 1999 Sep 24; 274(39):27351-8. View Abstract
  217. Sphingosine-1-phosphate: extracellular mediator or intracellular second messenger? Biochem Pharmacol. 1999 Jul 15; 58(2):201-7. View Abstract
  218. Differential pharmacological properties and signal transduction of the sphingosine 1-phosphate receptors EDG-1, EDG-3, and EDG-5. J Biol Chem. 1999 Jul 02; 274(27):18997-9002. View Abstract
  219. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J Biol Chem. 1999 Jun 11; 274(24):17042-8. View Abstract
  220. Cyclooxygenase-1 and -2 isoenzymes. Int J Biochem Cell Biol. 1999 May; 31(5):551-7. View Abstract
  221. Ligand-induced trafficking of the sphingosine-1-phosphate receptor EDG-1. Mol Biol Cell. 1999 Apr; 10(4):1179-90. View Abstract
  222. Cyclo-oxygenase-2 in vascular smooth muscle. Int J Mol Med. 1999 Jan; 3(1):41-8. View Abstract
  223. Lysophosphatidic acid stimulates the G-protein-coupled receptor EDG-1 as a low affinity agonist. J Biol Chem. 1998 Aug 21; 273(34):22105-12. View Abstract
  224. Dual actions of sphingosine-1-phosphate: extracellular through the Gi-coupled receptor Edg-1 and intracellular to regulate proliferation and survival. J Cell Biol. 1998 Jul 13; 142(1):229-40. View Abstract
  225. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science. 1998 Mar 06; 279(5356):1552-5. View Abstract
  226. Non-small cell lung cancer cycloxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs. Anticancer Res. 1998 Mar-Apr; 18(2A):775-82. View Abstract
  227. Dissociation of basal turnover and cytokine-induced transcript stabilization of the human cyclooxygenase-2 mRNA by mutagenesis of the 3'-untranslated region. Biochem Biophys Res Commun. 1998 Jan 26; 242(3):508-12. View Abstract
  228. The immediate-early gene product MAD-3/EDG-3/IkappaB alpha is an endogenous modulator of fibroblast growth factor-1 (FGF-1) dependent human endothelial cell growth. FEBS Lett. 1997 Sep 08; 414(2):419-24. View Abstract
  229. Tumorigenic transformation of immortalized ECV endothelial cells by cyclooxygenase-1 overexpression. J Biol Chem. 1997 Aug 22; 272(34):21455-60. View Abstract
  230. The mouse gene for the inducible G-protein-coupled receptor edg-1. Genomics. 1997 Jul 01; 43(1):15-24. View Abstract
  231. Involvement of nuclear factor kappa B in the regulation of cyclooxygenase-2 expression by interleukin-1 in rheumatoid synoviocytes. Arthritis Rheum. 1997 Feb; 40(2):226-36. View Abstract
  232. Down-regulation of cytokine-induced cyclo-oxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation. Biochem J. 1996 Aug 15; 318 ( Pt 1):325-31. View Abstract
  233. The inducible G protein-coupled receptor edg-1 signals via the G(i)/mitogen-activated protein kinase pathway. J Biol Chem. 1996 May 10; 271(19):11272-9. View Abstract
  234. Molecular characterization of the 5.2 KB isoform of the human cyclooxygenase-1 transcript. Prostaglandins. 1996 Jan; 51(1):81-5. View Abstract
  235. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett. 1995 Sep 18; 372(1):83-7. View Abstract
  236. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995 Sep 01; 55(17):3785-9. View Abstract
  237. Characterization of edg-2, a human homologue of the Xenopus maternal transcript G10 from endothelial cells. Biochim Biophys Acta. 1995 Jan 25; 1260(2):227-9. View Abstract
  238. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 1994 Nov; 271(2):927-34. View Abstract
  239. Structure of the human cyclo-oxygenase-2 gene. Biochem J. 1994 Sep 15; 302 ( Pt 3):723-7. View Abstract
  240. Induction of cyclooxygenase-2 by interleukin-1 alpha. Evidence for post-transcriptional regulation. J Biol Chem. 1994 Apr 22; 269(16):11769-75. View Abstract
  241. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J Clin Invest. 1994 Mar; 93(3):1095-101. View Abstract
  242. Cyclooxygenase gene expression in inflammation and angiogenesis. Ann N Y Acad Sci. 1993 Nov 30; 696:197-204. View Abstract
  243. Coexpression of phosphotyrosine-containing proteins, platelet-derived growth factor-B, and fibroblast growth factor-1 in situ in synovial tissues of patients with rheumatoid arthritis and Lewis rats with adjuvant or streptococcal cell wall arthritis. J Clin Invest. 1993 Feb; 91(2):553-65. View Abstract
  244. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci U S A. 1992 Aug 15; 89(16):7384-8. View Abstract
  245. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest. 1992 Jan; 89(1):97-108. View Abstract
  246. Cyclooxygenase gene expression is down-regulated by heparin-binding (acidic fibroblast) growth factor-1 in human endothelial cells. J Biol Chem. 1991 Dec 15; 266(35):24059-63. View Abstract
  247. Cytotoxic activity of chimeric proteins composed of acidic fibroblast growth factor and Pseudomonas exotoxin on a variety of cell types. FASEB J. 1991 Oct; 5(13):2843-9. View Abstract
  248. Production of platelet derived growth factor B chain (PDGF-B/c-sis) mRNA and immunoreactive PDGF B-like polypeptide by rheumatoid synovium: coexpression with heparin binding acidic fibroblast growth factor-1. J Rheumatol. 1991 Jan; 18(1):7-13. View Abstract
  249. Recovery of mitogenic activity of a growth factor mutant with a nuclear translocation sequence. Science. 1990 Sep 28; 249(4976):1567-70. View Abstract
  250. Cyclooxygenase is an immediate-early gene induced by interleukin-1 in human endothelial cells. J Biol Chem. 1990 Jul 05; 265(19):10805-8. View Abstract
  251. An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein-coupled receptors. J Biol Chem. 1990 Jun 05; 265(16):9308-13. View Abstract
  252. Isolation of immediate-early differentiation mRNAs by enzymatic amplification of subtracted cDNA from human endothelial cells. Biochem Biophys Res Commun. 1990 Mar 16; 167(2):637-43. View Abstract
  253. Structure-function relationships in sheep, mouse, and human prostaglandin endoperoxide G/H synthases. Adv Prostaglandin Thromboxane Leukot Res. 1990; 20:14-21. View Abstract
  254. Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci U S A. 1989 Oct; 86(19):7606-10. View Abstract
  255. Differential recovery of prostacyclin synthesis in cultured vascular endothelial vs. smooth muscle cells after inactivation of cyclooxygenase with aspirin. Prostaglandins Leukot Essent Fatty Acids. 1989 Jun; 36(3):175-84. View Abstract
  256. Reconstituted U1 small nuclear ribonucleoprotein complex restores 5' splice site cleavage activity. Biochem Biophys Res Commun. 1988 Aug 15; 154(3):1010-7. View Abstract
  257. Isolation of the cDNA for human prostaglandin H synthase. Prostaglandins. 1986 Dec; 32(6):829-45. View Abstract
  258. Recovery of prostacyclin synthesis in human vascular endothelial cells following intermittent or continuous exposure to indomethacin. Pharmacol Res Commun. 1985 May; 17(5):447-56. View Abstract
  259. Restoration of prostacyclin synthase in vascular smooth muscle cells after aspirin treatment: regulation by epidermal growth factor. J Lipid Res. 1985 Jan; 26(1):54-61. View Abstract
  260. Role of epidermal growth factor in cyclooxygenase synthesis. Adv Prostaglandin Thromboxane Leukot Res. 1985; 15:141-2. View Abstract

Contact Timothy Hla

Print Profile